Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Otávio T. Ranzani, Matt D. T. Hitchings, Rosana Leite de Melo, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

Modeling transmission of SARS-CoV-2 Omicron in China
Jun Cai, Xiaowei Deng, Juan Yang, et al.
Nature Medicine (2022) Vol. 28, Iss. 7, pp. 1468-1475
Open Access | Times Cited: 252
Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity
Francesco Menegale, Mattia Manica, Agnese Zardini, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2310650-e2310650
Open Access | Times Cited: 175
Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis
Wing Ying Au, Peter Pak‐Hang Cheung
BMJ (2022), pp. e069989-e069989
Open Access | Times Cited: 126
Epidemiological characteristics and transmission dynamics of the outbreak caused by the SARS-CoV-2 Omicron variant in Shanghai, China: A descriptive study
Zhiyuan Chen, Xiaowei Deng, Li‐Qun Fang, et al.
The Lancet Regional Health - Western Pacific (2022) Vol. 29, pp. 100592-100592
Open Access | Times Cited: 100
Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death
Zhuoying Huang, Shuangfei Xu, Jiechen Liu, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 81
Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization
Daniel R. Feikin, Laith J. Abu‐Raddad, Nick Andrews, et al.
Vaccine (2022) Vol. 40, Iss. 26, pp. 3516-3527
Open Access | Times Cited: 79
Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 78
Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies
Shangchen Song, Zachary J. Madewell, Ming‐Jin Liu, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 29
The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review
Aparajita Sarkar, Sara Omar, Aya Alshareef, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 24
Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study
Zhuoying Huang, Shuangfei Xu, Jiechen Liu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Congrui Zhu, Shengmei Pang, Jiaqi Liu, et al.
Drugs (2024) Vol. 84, Iss. 4, pp. 403-423
Closed Access | Times Cited: 9
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
Xiao‐Feng He, Jiao Su, Yunan Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
Jie Deng, Yirui Ma, Qiao Liu, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 17, pp. 10752-10752
Open Access | Times Cited: 35
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, et al.
BMJ (2023), pp. e074325-e074325
Open Access | Times Cited: 20
Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational COVID-19 studies
Korryn Bodner, Michael A. Irvine, Jeffrey C. Kwong, et al.
International Journal of Infectious Diseases (2023) Vol. 131, pp. 111-114
Open Access | Times Cited: 18
Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis
Shiyao Xu, Jincheng Li, Hongyuan Wang, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 16
Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron
Wilhelmine Meeraus, Abigail Postema, Christen Gray, et al.
Vaccine (2025) Vol. 53, pp. 126955-126955
Open Access
Comparison of vaccination and booster rates and their impact on excess mortality during the COVID-19 pandemic in European countries
O. V. Matveeva, Svetlana A. Shabalina
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Understanding the mechanisms for COVID-19 vaccine’s protection against infection and severe disease
Huijie Yang, Ying Xie, Changgui Li
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 186-192
Open Access | Times Cited: 12
Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose
Bruno Andraus Filardi, Valter Silva Monteiro, Pedro Vellosa Schwartzmann, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 683
Open Access | Times Cited: 12
Narrative Review of the Evolution of COVID-19 Vaccination Recommendations in Countries in Latin America, Africa and the Middle East, and Asia
Júlia Spinardi, Ana Carolina Dantas, Carolina Carballo, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 5, pp. 1237-1264
Open Access | Times Cited: 12
Dynamic Profiling and Prediction of Antibody Response to SARS-CoV-2 Booster-Inactivated Vaccines by Microsample-Driven Biosensor and Machine Learning
Sumin Bian, Min Shang, Ying Tao, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 352-352
Open Access | Times Cited: 4
Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study
Felippe Lazar Neto, Matt D. T. Hitchings, Avnika B. Amin, et al.
The Lancet Regional Health - Americas (2024) Vol. 34, pp. 100755-100755
Open Access | Times Cited: 4
Renewed global threat by the novel SARS-CoV-2 variants ‘XBB, BF.7, BQ.1, BA.2.75, BA.4.6’: A discussion
Ranjan K. Mohapatra, Ahmed Mahal, L. V. Simhachalam Kutikuppala, et al.
Frontiers in Virology (2022) Vol. 2
Open Access | Times Cited: 19
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
Moe H. Kyaw, Júlia Spinardi, Ling Zhang, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top